echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > 40 billion anti-digestion ulcer drug TOP10 products out! East Sunshine Medicine, Lepu... New products come, collections flock to

    40 billion anti-digestion ulcer drug TOP10 products out! East Sunshine Medicine, Lepu... New products come, collections flock to

    • Last Update: 2020-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Exciting content with the East Sunshine drug Aiomeprazole magnesium intestinal capsules, Bedpharmaceutical injection of Aiomeprazole sodium has been approved, as well as a number of local band procurement of proton pump inhibitor drugs included, proton pump inhibitors again by the market attentionAccording to The Net, sales of anti-peptic ulcer drugs at the end of public medical institutions in China in 2019 were RMB39,966 millionAnti-peptic ulcer drug products TOP10 are proton pump inhibitors, and sales are more than 1 billion yuan; in brand TOP10, Osekang's injectable omeprazole sodium with sales of 2.764 billion yuan ranked first, Zhengda Qing Pharmaceutical Group's injection of ameme ameprazole sales led with a growth rate of 23.28 percentAt present, Wuhan City, Fujian Province, Shandong Province, Jiangxi Province, Qinghai Province and other 6 regions will be PPI drugs included in the volume of procurement listEast Sunshine Medicine, Rohingya, Lepu..11 new PPI products hit recently, The East Sunshine Drug's Aiomeprazole magnesium intestinal capsule, Zhejiang Bede Pharmaceutical's injection of Esomeprazole sodium has been approved by the State Drug Administration for production, proton pump inhibitors (PPI) again by the market attentionAccording to the data of The Inner Net, a total of 11 proton pump inhibitor drugs have been approved in the domestic market so far in 2020, involving 3 varieties of injection of esiomeprazole, injection of lansola, aiomeprazole and other 3 varieties, and Lepu Pharmaceuticals is the only enterprise approved for 2 varietiesThe proton pump inhibitor drug Esomeprazole (Essomeprazole) approved to date 2020 is the first optical isomer body pump inhibitor to be used in clinical studies, mainly for the treatment of stomach ulcers, duodenal ulcers, peptic esophagitis and gastritisAiomeprazole was first developed by AstraZeneca, where its intestinal tablets were listed in the United States in 2001 and its injections in the United States in 2005At present, the domestic market editing form of Esomeprazole includes injections, intestinal tablets, intestinal lysis capsulesFrom 2020 to the present, six companies with esiomeprazole have been approved by six companies, including Betpharmaceutical, Lepu Pharmaceuticals, Nanjing Kofiping, Asia Pacific Pharmaceuticals, Shanghai Huilun and Zhuotai PharmaceuticalsEast Sunshine medicine approved aiomeprazole magnesium intestinal capsule seismovana is the first and exclusive variety in China, as is the same through the consistency evaluationAccording to, sales of Aiomeprazole, the terminal of Public Medical Center in China, in 2019 were 5.375 billion yuan, up 15.71 percent year-on-yearAmong them, injections accounted for 61.71 percent of the market share, intestinal tablets accounted for 31.46 percent, intestinal capsules accounted for 6.83 percent, AstraZeneca accounted for 63.23 percent of the market share, Zhengda Qing Pharmaceutical Group accounted for 21.07 percent, Oseikang accounted for 6.83 percentChina's public medical institutions terminal Aiomeprazole sales (units: 10,000 yuan) lansolaazole for the first generation of proton pump inhibitors, abenzerine derivative, is after omeprazole after another strong and effective proton pump inhibitorsLansoraawas was developed by Takeda and launched in the United States in 2004 with the injection of LansoraAt present, Lansorafen domestic market forms include injections, intestinal tablets, intestinal capsules, tablets, capsules From 2020 to the present, three enterprises have been approved for production of the injection of Lansora, namely, Rohingya Pharmaceuticals, Lepu Pharmaceuticals and Dijon Pharmaceuticals, a subsidiary of Rohingya Pharmaceuticals At present, a total of 25 pharmaceutical companies in the domestic market have injection lansolarazole production approval According to, sales of Lansorafen, the terminal of Public Medical Institutions in China, in 2019 amounted to 4.357 billion yuan, with injections accounting for 74.5% of the market share From the enterprise pattern, Luoxin Pharmaceuticals accounted for 25.42 percent of the market share, Orsaikang accounted for 20.28 percent, Yuekang Pharmaceuticals accounted for 12.08 percent China's public medical institutions terminal Lansolafen sales situation (units: 10,000 yuan) 40 billion anti-peptic ulcer drugs market, TOP10 products exposure of digestive system diseaseis is a more common disease, the course of the disease has chronic and recurrent characteristics, the main diseases include acute gastritis, chronic gastritis, peptic ulcers, functional indigestion, and the most common with functional indigestion and peptic ulcers According to, sales of peptic ulcer drugs were 39.966 billion yuan in 2019 in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (china's public medical institutions), up 1.01% year-on-year China's public medical institutions terminal treatment peptic ulcer drug sales (unit: 10,000 yuan) proton pump inhibitors are commonly used anti-peptic ulcer drugs At present, the domestic has been approved for the market of proton pump inhibitors are Aiomeprazole, omeprazole, Lansoola, Rebella, pyroprazole, eprazole and other 6 kinds As PPI drugs and related products in the domestic market has entered a mature period, and innovative drugs, anti-peptic ulcer drug market growth rate in recent years continued to slow In 2019, China's public medical institutions terminal anti-peptic ulcer drug products TOP10, proton pump inhibitors dominate the list, and sales are more than 1 billion yuan, of which Aiomeprazole magnesium intestinal tablet manufacturers only the original astrazenitos Sales of sodium in injection and lansola for injection decreased by more than 15% Injection sales of rebella sodium led the growth of 25.51 percent, with only Osekon, Rohingya Pharmaceuticals and Chang'ao Pharmaceuticals In 2019, China's public medical institutions terminal treatment peptic ulcer drug products TOP10 anti-peptic ulcer drug brand TOP10, Osecon and Asrican have 2 brands on the list, sales of more than 1 billion yuan of brands have 7 Osekang's injection-using omeprazole sodium topped the list with sales of 2.764 billion yuan, Zhengda Qing Pharmaceutical Group's injection-using aiomeprazole sales led by 23.28 percent growth rate, and Lizhu Group's exclusive product, Apraazole, sales of eprazole tablets also performed well 2019 China's public medical institutions terminal treatment peptic ulcer drug brand TOP10PPI drug collection surge hit! Osekon, Rohingya.. The winning bid entered 2020, provincial and local drug production volume everywhere flowering The database of the inner net consistency evaluation shows that the proton pump inhibitor drugs have 7 drugs (2 varieties) through the consistency evaluation, omeprazole intestinal lysis capsule evaluation enterprises have reached 4, respectively, Yangzijiang Pharmaceutical Group, Luoxin Pharmaceuticals, Hailing Pharmaceuticals, Changzhou four drugs Although proton pump inhibitor drugs were not included in the first and second batch of varieties list, but many regions of the band procurement list has been proton pump inhibitor drugs included PPI drugs through the consistency evaluation enterprises on May 26, Qinghai Provincial Medical Security Bureau issued a letter, to focus on the volume of procurement of 64 drugs, requiring local municipal medical institutions to report 64 drugs in 2019 actual procurement quantity and July 1, 2020 - June 30, 2021 expected purchase quantity Six proton pump inhibitors, such as Esomeprazole, Omeprazole, Lansolaazole, Rebellaazole, Pisoprazole, and Epraazole, are included in the list According to incomplete statistics, there are currently Wuhan City, Fujian Province, Shandong Province, Jiangxi Province, Qinghai Province and other 6 regions to the PPI drugs included in the volume of procurement list Wuhan belt procurement only for PPI injections, other areas of the belt procurement is taking into account proton pump inhibitor oral frequently released dosage forms, injections Proton pump inhibitor regional band procurement situation in Wuhan City, Fujian Province has been announced the volume procurement results, Wuhan City belt procurement of 5 proton pump inhibitors have a number of enterprises winning the bid, Osekang selected 3 varieties, AstraZeneca selected 2 varieties, Wutian, Luoxin Pharmaceuticals, Zhengda Tianqing Pharmaceutical Group and other products also have the winning bid Fujian Province drug tape procurement results have exclusive winning bid, Luoxin Pharmaceuticals, proton pump inhibitors, respectively, sea Cisco, Xinhua Pharmaceuticals At present, the drug band procurement in Shandong Province, Jiangxi Province and Qinghai Province is still in progress, and the results of the selection of proton pump inhibitors and other drugs are worthy of attention As the procurement of drug tape in various regions continues to advance, more regions will include proton pump inhibitors in the collection list in the future.
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.